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Key Points
• RB/RC induction fol-
lowed by ASCT is well
tolerated overall and
achieves high rates of
durable remissions.





and may predict dis-
ease recurrence.
The addition of high-dose cytarabine to rituximab/bendamustine (RB) induction could
improve outcomes for transplant-eligible patients with mantle cell lymphoma (MCL). We
conducted a pooled analysis of 2 phase 2 trials and an off-trial cohort each testing 3 cycles of
RB and 3 cycles of rituximab/high-dose cytarabine (RC) followed by autologous stem cell
transplantation (ASCT) among untreated, transplant-eligible patients with MCL. Dana-
Farber Cancer Institute (DFCI) andWashington University in St. Louis (WUSTL) led separate
phase 2 trials testing sequential and alternating cycles of RB/RC, respectively. Patients
treated at DFCI with sequential RB/RC off trial were retrospectively identiﬁed. Minimal
residual disease (MRD) was assessed in the DFCI trial. A total of 88 patients (23 DFCI trial, 18
WUSTL trial, and 47 off trial) received RB/RC; 92% of patients completed induction, and 84%
underwent planned consolidative ASCT. Grade 3 or 4 adverse events among trial patients
included lymphopenia (88%), thrombocytopenia (85%), neutropenia (83%), and febrile
neutropenia (15%). There were no treatment-related deaths during induction and 2
following ASCT. Among 87 response-evaluable patients, the end-of-induction overall and
complete response rates were 97% and 90%, respectively. After a median follow-up of 33
months, 3-year progression-free survival and overall survival were 83% and 92%,
respectively. Patients undergoing MRD testing experienced prolonged MRD negativity after
ASCT with emergence of MRD occurring in only 1 patient who subsequently relapsed. RB/RC
followed by ASCT achieves high rates of durable remissions in transplant-eligible patients
with MCL. These trials were registered at www.clinicaltrials.gov as #NCT01661881 (DFCI
trial) and #NCT02728531 (WUSTL trial).
Introduction
The adoption of novel induction regimens and the routine use of consolidation with autologous stem cell
transplantation (ASCT) in first remission have significantly improved outcomes for patients with mantle
cell lymphoma (MCL).1,2 Two randomized trials demonstrated that induction therapy with rituximab/
bendamustine (RB) improves progression-free survival (PFS) compared with RCHOP (rituximab,
cyclophosphamide, doxorubicin, vincristine, and prednisone).3,4 In addition, a phase 3 trial confirmed
that the addition of high-dose cytarabine to RCHOP-based induction therapy significantly improves PFS
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among transplant-eligible patients.5 Given the benefit of cytarabine
and the superiority of RB over RCHOP, the combination of RB and
cytarabine may provide a superior induction regimen prior to ASCT.
Indeed, the addition of low-dose cytarabine in combination with RB
yielded very successful results in 2 phase 2 trials among older,
transplant-ineligible patients.6,7 In 2012, Dana-Farber Cancer
Institute (DFCI) launched a phase 2 trial testing 3 cycles of RB
followed by 3 cycles rituximab and high-dose cytarabine (RC) in
23 transplant-eligible patients with untreated MCL. This regimen
achieved a complete response rate (CRR) of 96% and a 13-month
PFS of 96%.8 Based on these encouraging results, RB/RC
followed by ASCT became the standard frontline regimen for
transplant-eligible patients with MCL at DFCI. Simultaneously,
investigators at Washington University in St. Louis (WUSTL)
initiated a similar trial of alternating cycles of RB and RC in patients
with untreated MCL.
With the goal of providing a more robust estimate of the efficacy of
RB/RC, as well as its long-term outcomes, we conducted a pooled
analysis of the DFCI trial, the WUSTL trial, and a retrospective
series of transplant-eligible MCL patients who received RB/RC as
off-trial, first-line therapy at DFCI. In addition, we performed minimal
residual disease (MRD) testing during RB/RC induction and
following ASCT in a subset of patients. Herein, we report the




DFCI and WUSTL led independent phase 2 trials testing frontline
treatment with RB/RC in transplant-eligible patients with MCL.
Eligible participants were adults (aged 18-69 years in the DFCI trial
and 18-65 years in the WUSTL trial) with untreated, radiograph-
ically measurable, and pathologically confirmed MCL. Participants
were eligible for ASCT and had an Eastern Cooperative Oncology
Group (ECOG) performance status of 0 to 2, absolute neutrophil
count $1.0 3 109/L, platelet count $100 3 109/L, adequate renal
function (creatinine ,2.0 mg/dL [DFCI] or estimated glomerular
filtration rate $40 mL/min [WUSTL]), and preserved liver function
(transaminases #2.5 upper limit of normal [ULN] [DFCI] or #3.0
ULN [WUSTL] and total bilirubin #2.5 ULN [DFCI] or #2.0 ULN
[WUSTL]).
Patients with MCL who received frontline treatment with RB/RC
outside of a clinical trial were retrospectively identified using DFCI
pharmacy and transplant databases. Patients were included if they
were $18 years old, had a diagnosis of MCL (confirmed by DFCI
pathology review), initiated RB/RC therapy after 1 January 2014,
and had an end-of-induction (EOI) positron emission tomography/
computed tomography (PET/CT) available for review. Patients
evaluated at DFCI were included if they received their treatment at
DFCI or at a community center.
Both clinical trials and the retrospective review were approved
by relevant institutional review boards and were conducted in
accordance with principles defined by the Declaration of Helsinki.
All trial patients provided informed consent, and a waiver of
informed consent was granted for retrospective analysis of nontrial
patients.
Treatment
Treatment of each cohort consisted of 3 cycles of outpatient RB
(rituximab 375 mg/m2 [day 1] and bendamustine 90 mg/m2 [days 1
and 2] every 4 weeks) and 3 cycles of inpatient RC (rituximab
375 mg/m2 [day 1] and cytarabine every 12 hours for 4 doses [days
1 and 2] every 3 weeks). The starting dose of cytarabine was 3 g/m2
in the DFCI and WUSTL trials, with dose reductions for age, renal
dysfunction, and/or neurotoxicity (Figure 1). After enrollment of 14
patients in the WUSTL trial, the WUSTL protocol was amended to
lower the starting cytarabine dose to 2 g/m2 for subsequent
patients due to frequent prolonged thrombocytopenia following
ASCT. In patients treated off trial, cytarabine dose was chosen by
the treating physicians.
The DFCI trial and off-trial cohorts used sequential cycles of RB
(cycles 1-3) followed by RC (cycles 4-6), whereas the WUSTL trial
tested alternating cycles of RB (cycles 1, 3, and 5) and RC (cycles
2, 4, and 6) (Figure 1). Growth factor support and prophylactic
fluoroquinolone treatment were used during RC cycles in the DFCI
and WUSTL trials. In the retrospective cohort, growth factor
support and antibiotic prophylaxis were determined by the treating
physician.
Response assessment
Patients in all cohorts underwent imaging assessments at baseline
and at the end of induction. The DFCI trial, which was designed
before guideline recommendation for fluorodeoxyglucose (FDG)
PET/CT use in MCL, used CT, and response assessments were
based on the International Working Group Criteria.9 The WUSTL
and off-trial cohorts used FDG-PET/CT, and responses were
assessed using the 2014 Lugano classification.10 FDG-PET/CT
scans for all off-trial patients were reviewed by an expert DFCI
nuclear medicine radiologist. Both trials mandated a baseline bone
marrow aspirate and biopsy, and if positive, a repeat bone marrow
aspirate and biopsy after induction therapy to confirm response.
Flow cytometry was not required for response reassessment.
Autologous transplantation
Stem cell mobilization and leukapheresis were performed based on
institutional standards (filgrastim with plerixafor used as needed for
poor mobilizers) and were not a part of either phase 2 trial. ASCT
conditioning consisted of either CBV (cyclophosphamide, carmus-
tine, and etoposide) in 13 patients transplanted at DFCI before 15
April 2014 or BEAM (carmustine, etoposide, cytarabine, and melphalan)
in all other patients. Radiographic assessments after ASCT were at
the discretion of treating physicians.
MRD assessment
When feasible, peripheral blood mononuclear cells (PBMCs) and
plasma were collected from patients enrolled on the DFCI trial at
baseline, after 3 cycles of induction, after 6 cycles of induction, and
every 3 to 6 months thereafter. Samples were assessed for MRD
using immunoglobulin-based next-generation sequencing (IgNGS)
with the ClonoSeq platform (Adaptive Biotechnologies, Seattle,
WA), as previously described.11,12 The analytical sensitivity of the
ClonoSeq platform is estimated at detection of 1 clonal molecule in
a background of 13 106 nonclonal molecules. As the average input
into the IgNGS reaction for PBMCs was 1.79 3 106 genomes, the
nominal sensitivity for this assay is 1 in 1 3 106. For detection of
plasma circulating tumor DNA (ctDNA), the average input into the
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IgNGS reaction was 1.96 3 104 genomes; therefore, the nominal
sensitivity of the assay for plasma samples is 1 in 1.96 3 104. MRD
testing was considered positive for any nonzero result in either
plasma or PBMCs.
Statistical analysis
The primary end point of the DFCI trial was ORR, as previously
reported.8 The primary end point of the WUSTL trial was stem cell
mobilization success rate (defined as a yield .2 3 106 CD341
stem cells/kg). PFS and overall survival (OS) were estimated using
the Kaplan-Meier method, and differences in survival between
groups were assessed using log-rank tests. PFS was defined as the
time from initiation of RB/RC to death from any cause, relapse, or
progression, with patients censored at the last time seen alive and
progression-free. OS was defined as the time from initiation of RB/
RC to death from any cause, with patient censored at the last time
seen alive. Between groups, nominal, continuous, and ordinal
variables were compared by Fisher’s exact test, Kruskal-Wallis rank-
sum, or Kruskal-Wallis trend test, respectively. Univariate Cox
proportional hazards regression were used to evaluate associations
between prognostic factors and PFS, and Wald P values were
reported for covariates. All analyses were performed using R
version 3.5.0 (2018-04-23, R Core Team).
Results
Patients and treatment
The DFCI trial enrolled 23 patients from August 2012 to March
2014. The WUSTL trial enrolled 18 patients from August 2016 to
September 2018. Forty-seven patients initiated RB/RC therapy
outside of a clinical trial between July 2014 and August 2018 and
were included in the off-trial cohort. The baseline characteristics of
all 88 patients are summarized in Table 1. The median age was
58 years (range, 30-72). Seventeen patients (19%) had a high MIPI
score, 21 (24%) had a Ki67 .30%, and 11 (12%) had blastoid or
pleomorphic histology. WUSTL trial patients had more frequent
high-risk features (ECOG performance status of 2, high MIPI,
blastoid/pleomorphic histology) compared with the other cohorts.
All trial patients were treated at an academic center, whereas 8 out
of 47 off-trial patients (17%) received all 6 cycles of RB/RC at
a community center. Among off-trial patients, where the starting
dose of cytarabine was determined by the treating physician,
a cytarabine dose of ,3 g/m2 was used more frequently compared
with patients treated on the DFCI or WUSTL trials (83% vs 39% vs
44%, P , .001). In total, 31 out of 47 off-trial patients (66%)
received a lower starting dose of cytarabine than intended per the
DFCI trial protocol (median starting cytarabine dose: off-trial cohort,
2 g/m2; DFCI trial, 3 g/m2; WUSTL trial, 3 g/m2). Among all cohorts,
24 patients (27%) had either a dose reduction in cytarabine or
received ,3 cycles of RC (17 patients with dose reduction only, 5
patients with $1 missed RC cycles, and 2 patients with both dose
reductions and missed RC cycles). Rates of cytarabine modification
were higher in the off-trial cohort (14/47 [30%]) and WUSTL trial
(9/18 [50%]) compared with the DFCI trial (1/23 [4%]) (P , .01).
The median cumulative dose of cytarabine was 24 g/m2 among all
patients (24 g/m2 in the off-trial cohort, 36 g/m2 in the DFCI trial
cohort, and 24 g/m2 in the WUSTL trial cohort).
Efficacy
One patient (WUSTL trial) was removed from the trial prior to an
EOI assessment due to a type III hypersensitivity reaction to
rituximab. Among 87 response-evaluable patients, the EOI overall
response rate (ORR) was 97% (90% complete response [CR]; 7%
partial response [PR]), 96% (96% CR; 0% PR) in the DFCI trial,
100% (CR 94% CR, 6% PR) in the off-trial cohort, and 88% (CR
71%; PR 18%) in the WUSTL trial (Table 2). High ORRs were
observed for poor-risk patient subgroups (Table 2). Response rates
were similar among patients receiving a starting cytarabine dose of
3 g/m2 (ORR, 100%; CRR, 89%) and ,3 g/m2 (ORR, 95%; CRR,
89%) (P 5 .55 for ORR, P 5 1.00 for CRR). Similarly, among
patients completing 3 cycles of RC, cumulative cytarabine dose
was not a significant predictor of response (Table 2).
Seventy-four patients (84%) underwent planned ASCT after RB/
RC induction, including 21 out of 23 (91%) in the DFCI trial, 14 out
of 18 (78%) in the WUSTL trial, and 39 out of 47 (83%) in the off-
trial cohort. One additional patient in the off-trial cohort was
scheduled to undergo ASCT after the time of data lock, while 13
patients did not undergo ASCT due to persistent or progressive
disease (n 5 4), persistent cytopenias (n 5 3), patient or physician
preference (n 5 4), inadequate stem cell collection (n 5 1), and an
incidental ASXL1 mutation without cytopenias (n 5 1). Among
patients with$90 days of follow-up after ASCT, 27 out of 74 (36%)
RB RC
RB x 3 RC x 3
WUSTL phase II trial (n=18) (2016-2018)
DFCI phase II trial (n=23) (2012-2014)




•  Rituximab – 375 mg/m2, day 1
•  Bendamustine – 90 mg/m2, days 1-2
RC
•  Rituximab – 375 mg/m2, day 1
•  Cytarabine – 3 gm/m2 BID days 1-2*
RB RC RB RC
Figure 1. Treatment schema: a pooled analysis of 2 phase 2 clinical trials and a retrospectively identified nontrial cohort. In each cohort, patients received 3
cycles of RB and 3 cycles of RC. In the DFCI trial, the starting dose of cytarabine was reduced from 3 g/m2 to 2 g/m2 for patients .60 years with a further dose reduction to
1.5 g/m2 for patients .60 years with either renal dysfunction (creatinine, 1.3-2.0) or preexisting neurotoxicity or 1.0 g/m2 for patients .60 years with both renal dysfunction
and preexisting neurotoxicity. In the WUSTL trial, the starting dose of cytarabine was reduced to 2 g/m2 for patients .60 years and/or with renal dysfunction (estimated
glomerular filtration rate, 40-59). *The starting cytarabine dose was chosen by the treating physician for patients treated in the nontrial cohort. BID, twice a day.
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received rituximab maintenance therapy. Maintenance rituximab
was not mandated in either trial and was used more frequently in
more recent cohorts (DFCI, 2/21 [10%]; DFCI off-trial, 16/39
[41%]; WUSTL, 9/14 [64%]).
Median follow-up for all patients was 33.0 months (DFCI trial, 60.9
months; off-trial cohort, 30.9 months; WUSTL trial, 22.1 months).
Among the entire study population, 3-year PFS was 83% (95%
confidence interval [CI], 75% to 93%) (Figure 2). In the DFCI trial,
the 1-year, 3-year, and 5-year PFS rates were 96%, 87%, and 87%,
respectively. In the off-trial cohort, the 1-year and 3-year PFS rates
were 98% and 85%, respectively. In the WUSTL trial, the 1-year
and 2-year PFS rates were 83% and 75%, respectively. In
a univariate analysis, high MIPI (hazard ratio [HR], 4.25; 95% CI,
1.19-15.13; P 5 .026) and blastoid/pleomorphic histology (HR,
3.47; 95% CI, 1.07-11.19; P 5 .038) were associated with inferior
PFS (Figure 3). The 3-year PFS rates for patients with high MIPI
score and blastoid/pleomorphic histologies were 76% (38% to
92%) and 66% (27% to 88%), respectively. There was no significant
association between PFS and sex, Ki67.30%, location of treatment,
treatment cohort, or starting cytarabine dose (Figure 3). Among 81
patients who completed 3 cycles of RC, cumulative cytarabine dose
Table 1. Baseline characteristics
Total (N 5 88)
Patient cohort, n (%)
PDFCI off-trial (n 5 47 [53%]) DFCI trial (n 5 23 [26%]) WUSTL trial (n 5 18 [20%])
Age, y
Median (range) 58 (30-72) 58 (30-72) 57 (42-69) 60 (38-65) .97*
.60 36 (41) 20 (43) 8 (35) 8 (44) .84†
Male sex 64 (73) 32 (68) 15 (65) 17 (94) .056†
Stage at diagnosis
1 1 (1) 0 (0) 0 (0) 1 (6) .80‡
2 1 (1) 1 (2) 0 (0) 0 (0)
3 11 (12) 7 (15) 3 (13) 1 (6)
4 75 (85) 39 (83) 20 (87) 16 (89)
ECOG PS
0-1 84 (95) 47 (100) 22 (96) 15 (83) .013†
2 4 (5) 0 (0) 1 (4) 3 (17)
Days from diagnosis to treatment, median (range) 32 (0-1539) 31 (3-1388) 40 (12-245) 21 (0-1539) .031*
MIPI score
Low 47 (53) 22 (47) 16 (70) 9 (50) .13‡
Intermediate 16 (18) 11 (23) 5 (22) 0 (0)
High 17 (19) 6 (13) 2 (9) 9 (50)
Missing 8 (9) 8 (17) 0 (0) 0 (0)
LDH > ULN
No 54 (61) 27 (57) 18 (78) 9 (50) .16†
Yes 27 (31) 13 (28) 5 (22) 9 (50)
Missing 7 (8) 7 (15) 0 (0) 0 (0)
Ki67
#30% 49 (56) 27 (57) 12 (52) 10 (56) ..99†
.30% 21 (24) 12 (26) 5 (22) 4 (22)
Missing 18 (20) 8 (17) 6 (26) 4 (22)
MCL subtype
Other 76 (86) 40 (85) 23 (100) 13 (72) .037†
Blastoid/pleomorphic 11 (12) 7 (15) 0 (0) 4 (22)
Missing 1 (1) 0 (0) 0 (0) 1 (6)
Treating center
Community 8 (9) 8 (17) 0 (0) 0 (0) .025†
Academic 80 (91) 39 (83) 23 (100) 18 (100)
Significant P values (ie, P , .05) are bolded.
LDH, lactate dehydrogenase; MIPI, MCL International Prognostic Index; PS, performance status.
*Kruskal-Wallis rank-sum test.
†Fisher’s exact test.
‡Kruskal-Wallis trend test (Monte Carlo simulation with 10 000 replicates).
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was not a significant predictor of PFS (cumulative cytarabine dose
.24 g/m2 vs #24 g/m2; HR, 2.20; P 5 .25). Among 74 patients
who underwent ASCT, there was no significant difference in PFS
among patients who received rituximab maintenance (HR, 0.28;
95% CI, 0.03-2.25; P 5 .23). Overall, the 3-year OS was 92%
(95% CI, 85% to 98%) and was similar across study cohorts
(Figure 2).
Toxicity
A total of 81 patients (92%) completed 6 cycles of RB/RC. Seven
patients (8%) discontinued therapy due to persistent cytopenias
occurring during RC cycles (n 5 2), progressive disease (n 5 2),
physician preference (n 5 1), grade 3 rash attributed to
bendamustine (n5 1), or grade 3 type III hypersensitivity reaction to
rituximab (n 5 1). Treatment discontinuation appeared to be more
common in patients receiving alternating cycles compared with
sequential cycles of RB/RC (17% vs 6%, P 5 .15). Detailed
adverse event (AE) logs were maintained for patients participating
in both phase 2 trials (n 5 41). As expected, rates of grade 3 or 4
hematologic AEs were high, particularly during RC cycles (Table 3;
supplemental Table 1). In total, 80% of patients developed grade 4
thrombocytopenia, and 68% experienced grade 4 neutropenia.
Grade 3 or 4 infectious complications included febrile neutropenia
in 6 patients (15%) as well as enterocolitis, pneumonia, and sepsis
each in 1 patient (2% each). Other nonhematologic grade AEs
were less frequent and mostly grade 1 or 2 (supplemental Tables 1
and 2). In the off-trial cohort, AEs requiring hospitalizations occurred
in 14 patients (30%), including febrile neutropenia (22%), rash
(2%), atrial fibrillation with rapid ventricular response (2%), tumor
lysis syndrome during cycle 1 of RB in a patient with preexisting
chronic kidney disease (2%), Escherichia coli sepsis (2%), and
cryptogenic organizing pneumonia attributed to rituximab (2%).
Seventy-four of 75 patients (99%) in whom stem cell mobilization
was attempted successfully collected CD341 stem cells for ASCT
(median 3.63 106 cells/kg). Patients required a mean of 1.96 days
for collection (median, 2 days; range, 1-6 days). Plerixafor was used
for mobilization in 44 out off 75 patients (59%), including 12 out of
21 (57%) in the DFCI trial, 14 out of 14 (100%) in the WUSTL trial,
and 18 out of 40 (45%) in the off-trial cohort. Delayed platelet
engraftment after ASCT was seen more often in patients receiv-
ing alternating cycles of RB/RC compared with sequential RB/RC
(day 30 platelets ,50 3 109/L, 58% vs 14%, P 5 .002; day 100
platelets ,100 3 109/L, 67% vs 18%, P 5 .002). An initial
cytarabine dose of 3 g/m2 was also associated with impaired
platelet recovery (day 30 platelets ,50 3 109/L, 38% vs 10%,
P 5 .007).
There were no treatment-related deaths during RB/RC induction.
Following ASCT, there were 2 transplant-related deaths. One
patient died suddenly from an unknown cause 13 days after
ASCT. No autopsy was performed. A second patient succumbed
to a respiratory syncytial virus infection and respiratory failure
56 days after ASCT. A third patient was diagnosed with progressive
multifocal leukoencephalopathy ;6 months after ASCT and
4 months after initiating rituximab maintenance and is currently in
stable condition.
MRD
Among 23 patients enrolled in the DFCI trial, tumor clonotypes
could be identified for MRD assessment in 20 patients (87%).
Eighteen of these patients had blood samples at $1 time point for
MRD analysis, including 12 samples at baseline, 11 after 3 cycles of
RB, 12 at EOI, and 112 at various time points after ASCT. All
baseline samples were positive for ctDNA in PBMCs or plasma.
MRD was detected in 3 out of 11 (27%) samples after 3 cycles of
RB, 1 out of 12 EOI (8%) samples, and 0 out of 15 (0%) samples
collected 3 months after ASCT. There was no correlation between
interim or EOI MRD positivity and PFS (Figure 4). Among 17
patients with post-ASCT blood samples, 2 patients relapsed
(patient A, 21 months after ASCT; and patient B, 62 months after
ASCT). Patient B had 5 initial negative MRD samples, but ctDNA
was detected in both PBMCs and plasma 7.2 months before
clinical relapse. Patient A had 2 MRD assessments, collected 13.5









































































































*Response assessment in the DFCI trial was based on CT using the International
Working Group Criteria.9 Responses in other cohorts were based on PET using the
Lugano classification.10
†Among the 81 patients who completed 3 cycles of RC.
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and 11 months prior to relapse, which were both negative. A sample
at the time of relapse was not available for assessment. All other
post-ASCT samples have been negative for MRD.
Discussion
In our pooled analysis, RB/RC induction followed by ASCT was
associated with high rates of durable remissions in transplant-
eligible patients with MCL. Prior studies suggest that deeper
remissions before ASCT assessed either radiographically13 or
molecularly5,14-17 are associated with improved long-term out-
comes. In our study, 90% of patients achieved a CR at the EOI.
In addition, MRD testing from a subset of patients suggests that
RB/RC induction achieves high rates of MRD negativity that
persists for years following ASCT in most patients. High-risk patient
groups (high MIPI, blastoid/pleomorphic histology, Ki67 .30%)
each achieved CRRs $75%, but remissions appeared to be less
durable for patients with high MIPI scores and blastoid/pleomorphic
histology. Differences in frequencies of these patients appeared
to explain the lower response rates and trend toward inferior
PFS observed in the WUSTL trial, which included more high-risk
patients.
RB/RC induction was generally well tolerated with expected,
manageable rates of hematologic and infectious AEs. RB/RC did
not impair the successful collection of autologous stem cells for
transplantation, but delayed platelet recovery was observed in some
patients after ASCT, particularly among those who received 3 g/m2
cytarabine and/or alternating cycles of RB/RC. Since neither higher
cytarabine doses nor alternating cycles of RB/RC were associated
with improvement in response rates or PFS, we would recommend
sequential cycles of RB/RC with 2 g/m2 dosing of cytarabine for
clinical practice and for future trials that adopt this regimen.
Cross-trial comparisons are inherently challenging due to differ-
ences in patient populations and response assessment. Acknowl-
edging these limitations, the 3-year PFS of 83% compares favorably
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DFCI off–trial: HR 1.84 [0.46, 7.27], p = 0.39
WUSTL trial: HR 4.14 [0.85, 20.20], p = 0.079
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DFCI off–trial: HR 0.60 [0.09, 4.09], p = 0.60
WUSTL trial: HR 2.03 [0.28, 14.83], p = 0.48
D
Figure 2. PFS and OS. PFS (A), PFS by cohort (B), OS (C), and OS by cohort (D).
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with that seen with other cytarabine-based induction regimens.5,13,18
Approximately half of the patients in this study were treated outside
of a clinical trial. These patients had low rates of treatment
discontinuation due to toxicity and achieved similarly durable
remissions, suggesting that RB/RC is an effective choice of induction
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Figure 3. Univariate Cox regression for PFS.
Table 3. Serious AEs for trial (DFCI/WUSTL) patients
DFCI WUSTL Combined
Grade 3-4 (n 5 23 [56%]) Grade 3 Grade 4 Grade 3-4 (n 5 18 [44%]) Grade 3 Grade 4 Grade 3-4 (n 5 41) Grade 3 Grade 4
Lymphopenia 21 (91) — 21 (91) 15 (83) 1 (6) 14 (78) 36 (88) 1 (2) 35 (85)
Thrombocytopenia 19 (83) — 19 (83) 16 (89) 2 (11) 14 (78) 35 (85) 2 (5) 33 (80)
Neutropenia 20 (87) 2 (9) 18 (78) 14 (78) 4 (22) 10 (56) 34 (83) 6 (15) 28 (68)
Leukopenia 18 (78) — 18 (78) 13 (72) 1 (6) 12 (67) 31 (76) 1 (2) 30 (73)
Anemia 11 (48) 11 (48) — 7 (39) 6 (33) 1 (6) 18 (44) 17 (41) 1 (2)
Febrile neutropenia 4 (17) 3 (13) 1 (4) 2 (11) 1 (6) 1 (6) 6 (15) 4 (10) 2 (5)
Fever 2 (9) 2 (9) — — — — 2 (5) 2 (5) —
Enterocolitis — — — 1 (6) 1 (6) — 1 (2) 1 (2) —
Pneumonia 1 (4) 1 (4) — — — — 1 (2) 1 (2) —
Sepsis 1 (4) 1 (4) — — — — 1 (2) 1 (2) —
Hyperglycemia — — — 1 (6) 1 (6) — 1 (2) 1 (2) —
Hyperuricemia — — — 1 (6) — 1 (6) 1 (2) — 1 (2)
Infusion related reaction — — — 1 (6) 1 (6) — 1 (2) 1 (2) —
Thrombotic thrombocytopenic purpura 1 (4) — 1 (4) — — — 1 (2) — 1 (2)
Data are presented as n (%) of patients.

















L user on 04 M
arch 2020
By pooling data from 2 phase 2 trials and a cohort of nontrial
patients, we were able to compare safety across different dosing
schedules, assess real-world outcomes outside of a clinical trial,
and examine outcomes among high-risk patient subsets. However,
pooling data from different cohorts has inherent limitations. In this
case, the pooled phase 2 trials had different primary end points,
dosing schedules, dose modifications, and response assessments.
In addition, among patients treated outside of a clinical trial, the
starting dose cytarabine was lower than that used among trial
patients. These limitations should be considered when interpreting
the results, particularly when comparing data across patient cohorts.
While inclusion of off-trial patients provides important information
about real-world outcomes with this regimen, it also introduces the
possibility of selection bias. In this case, the possibility of bias is
minimized by the fact that RB/RC was the institutional standard
practice during the study timeframe. Detailed toxicity results from
the 2 clinical trials suggest that RB/RC can be delivered safely.
While toxicity data for nontrial patients are less robust, limited AE
information, rates of treatment discontinuation, treatment-related
mortality, and post-ASCT safety were similar in the off-trial cohort.
EOI response assessment was not uniform across study cohorts,
reflecting the relatively recent implementation of PET as the
preferred imaging modality in MCL. This limits our ability to compare
across study cohorts, but RB/RC appears to have excellent activity
based on either PET or CT imaging. TP53 deletion/mutation testing
was not performed for either clinical trial or as part of standard
practice for off-trial patients, so we cannot comment on its
prognostic significance. Finally, longer follow-up will be helpful in
confirming that the favorable outcomes observed with RB/RC are
durable.
Because induction and consolidative ASCT are not curative and are
associated with significant morbidity, many trials are seeking to
improve outcomes by incorporating novel agents, like Bruton
tyrosine kinase inhibitors, into first-line regimens. An upcoming US
Intergroup randomized trial (EA4181) will determine if the addition
of acalabrutinib to an RB/RC-based chemotherapy backbone can
improve EOI MRD negativity in untreated patients with MCL. This
trial and others are increasingly using MRD as a primary measure of
efficacy and a tool to tailor the intensity of frontline treatment. MRD
testing using allele-specific oligonucleotide polymerase chain
reaction has previously been successfully used to track depth of
response following ASCT and initiate pre-emptive treatments in
high-risk patients.14,15 In our study, MRD testing using IgNGS
(ClonoSeq) was feasible for nearly all patients, had a high negative
predictive value, and identified the presence of ctDNA in a relapsing
patient 7.2 months prior to clinical recurrence. Future trials should
consider mandatory long-term sample collection for MRD assess-
ment to further evaluate the operating characteristics of IgNGS
MRD testing following ASCT. While additional events and longer
follow-up are necessary, our results suggest that IgNGS could be
a useful tool for tracking MRD following ASCT and predicting
impending recurrence.
In conclusion, induction therapy with RB/RC followed by ASCT was
well tolerated and achieved high rates of durable remissions in 2
phase 2 clinical trials and among a cohort of off-trial patients. RB/
RC is therefore an effective option for induction therapy in
transplant-eligible patients with MCL.
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Figure 4. MRD analysis. When feasible, patients in the DFCI trial cohort had samples collected at baseline, after 3 cycles of induction therapy, after 6 cycles of induction
therapy, and at various time points following ASCT for MRD analysis using Ig-NGS with ClonoSeq (Adaptive Biotechnologies). In this swimmer’s plot, each horizontal arrow
represents an individual patient. Yellow lines denote patients who have relapsed, and the time of relapse is marked by a red x. Green patients are progression-free. Purple
triangles represent the timing of ASCT, red circles are MRD-positive samples, and blue circles are MRD-negative samples.
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